ReviewFrontiers in nutrition2025
Altered mitochondrial function: a clue therapeutic strategies between metabolic dysfunction-associated steatotic liver disease and chronic kidney disease?
Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Immunometabolic Remodeling in Osteosarcopenia: Inflammaging, Mitochondrial Dysfunction, Gut-Derived Metabolites and Therapeutic Opportunities.Metabolites · 2026Review
- Metabolic Dysfunction-associated Steatotic Liver Disease and Chronic Kidney Disease: From Epidemiology and Pathophysiology to Clinical Prediction and Treatment Options.Journal of clinical and translational hepatology · 2026Review
- Metabolic dysfunction-associated steatotic liver disease as a systemic disorder: extrahepatic manifestations and the need for data-driven phenotyping.Frontiers in endocrinology · 2026Review
- Microfluidic innovations in chronic kidney disease and renal fibrosis: from mechanistic insights to clinical applications.Frontiers in medicine · 2026Review
- A novel palmitoylation-based molecular signature reveals COX6A1 as a key regulator in metabolic dysfunction-associated steatotic liver disease.Journal of translational medicine · 2025Article
- Reconciling diagnostic definitions for proposing metabolic dysfunction-associated steatotic liver disease in chronic kidney disease risk.Hepatobiliary surgery and nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic kidney disease (CKD) have been demonstrated to be intricately linked in a multitude of research studies. The reclassification of MASLD has prompted a reevaluation of its epidemiological patterns and the associated risk of CKD. This is crucial as MASLD, focusing on cardiometabolic factors, might have a more pronounced association with CKD than NAFLD. Additionally, mitochondrial dysfunction has been implicated in the pathogenesis of both MASLD and CKD. Studies on metabolic dysfunction-associated steatohepatitis mouse models have revealed significant mitochondrial alterations, such as loss of cristae and impaired function in the kidneys, underscoring the critical importance of mitochondrial integrity in these pathologies. This review offers an extensive overview of the existing literature, covering the following key aspects: (a) presenting the latest epidemiological findings that elucidate the relationship between MASLD and CKD; (b) kidney pathological changes associated with MASLD; (c) mitochondrial alterations in MASLD and CKD, including oxidative stress, dynamics, and mitophagy; and (d) potential mitochondrial-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.